Predicting response to enzalutamide and abiraterone in metastatic prostate cancer using whole-omics machine learning

HIGHLIGHTS

• who: Anouk C. Jong from the , biopsy study (NCT01855477) has been approved by the medical ethical committee of the University Medical Center Utrecht and has been conducted in accordance with the Declaration of HelsinkiIn- and exclusion criteria were published before20, , . In short, patients were eligible if they had a locally advanced or metastatic solid tumor for which a next line of systemic treatment with a registered anti-cancer agent was indicated, and a safe tumor biopsy could be obtained. All patients provided written informed consent before any study procedures were performed. Compensation for participation was not provided . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.